Press release
Digitized Predictive Analysis To Drive The U.S Bacterial Conjunctivitis Drugs Market At A CAGR Of 2.7%
The U.S Bacterial Conjunctivitis Drugs Market is estimated to grow on a diligent note in the forecast period. Today, social proof could be equated with digital currency. In other words, people go for digital reviews, signals, and testimonials before deciding on the doctor/hospital. This social proof works better with telehealth, and also goes beyond region-wise obstacles. This would all be about the healthcare vertical going forward.According to a new market report published by Persistence Market Research "The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be the Largest Segment by 2024" the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR of 2.7% from 2012 to 2018 and (-3.73%) from 2018 to 2024.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/5192
Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical).
Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year.
Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years.
Major organizations profiled in this report include:
Actavis plc.
Akorn, Inc.
Bayer AG.
F. Hoffmann-La Roche, Ltd.
Merck & Co., Inc.
Novartis AG.
Perrigo Company plc, Pfizer, Inc.
Santen Pharmaceutical Co., Ltd.
Valeant Pharmaceuticals International, Inc.
Additionally.
Other.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/5192
Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S.
It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study.These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country.
Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a share of more than 70% in 2013. Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/5192
However, the segment is expected to witness a significant decline in sales in the near future -from a CAGR of 4.9% from 2012 to 2018 to a CAGR of (-8.1%) from 2018 to 2024. Burgeoning influx of generic antibacterials as well as upcoming patent expiries of leading branded formulations such as Vigamox, Zymaxid, Moxeza, and Besivance are a few major factors that would adversely affect the growth of the segment.
With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the bacterial conjunctivitis drugs market in the U.S. Hence, the future market growth would be contingent on commercialization of novel drugs for new indications.
However, it has been observed that although the incidence rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, due to which the novel product pipeline for bacterial conjunctivitis is weak/dry. At present, only a few novel compounds are under investigation in both preclinical and clinical settings for the treatment of bacterial conjunctivitis.
Complete Report Details@ https://www.persistencemarketresearch.com/market-research/u.s-bacterial-conjunctivitis-drugs-market.asp
The U.S. bacterial conjunctivitis drugs market is segmented as follows:
U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
Fluoroquinolones
Ciprofloxacin
Ofloxacin
Levofloxacin
Moxifloxacin
Gatifloxacin
Besifloxacin
Aminoglycosides
Tobramycin
Gentamycin
Macrolides
Erythromycin
Azithromycin
Others
U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
Vancomycin Ophthalmic Ointment
Early Stage (Phase I and Phase II trials) - Tabular Representation
Related Reports:
Clostridium Difficile Infection Treatment Market - https://www.persistencemarketresearch.com/market-research/clostridium-difficile-infection-treatment-market.asp
Immune Checkpoint Inhibitors Market - https://www.persistencemarketresearch.com/market-research/immune-checkpoint-inhibitors-market.asp
Contact Us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Digitized Predictive Analysis To Drive The U.S Bacterial Conjunctivitis Drugs Market At A CAGR Of 2.7% here
News-ID: 2642013 • Views: …
More Releases from Persistence Market Research

Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market
The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to…

Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market
The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in…

US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market
The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According…

Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market
The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained…
More Releases for Bacterial
Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market?
The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training.
The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at…
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current…
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…